Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cellnaivety

CELLNAIVETY SIGNED

Deciphering the Molecular Foundations and Functional Competence of Alternative Human Naïve Pluripotent Stem Cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CELLNAIVETY project word cloud

Explore the words cloud of the CELLNAIVETY project. It provides you a very rough idea of what is the project "CELLNAIVETY" about.

ipsc    competence    benefit    isolation    principles    paradigm    damaged    esc    identity    models    engineered    ipscs    developmental    identical    disease    mice    pluripotent    mouse    hurdles    restrain    cell    genetically    create    cross    species    pluripotency    maintenance    possibilities    signalling    termed    es    microscopy    screening    an    reprogramming    earlier    vitro    goals    patient    vivo    dissecting    shift    escs    functional    fulfilling    therapy    synergistically    humans    epigenetic    stem    ex    embryonic    embryo    safety    cas9    correspond    somatic    cells    limited    safe    ve    governing    tissues    utilizing    conventional    human    medical    reside    flexible    na    alleviate    iuml    accelerate    humanized    variability    naive    unveil    capacity    transplantation    direct    customized    genome    simplistic    limitations    diseases    chimeric    strategies    primed    culture    platforms    programming    opens    differentiation    constitutes    restore    transcriptional    crispr   

Project "CELLNAIVETY" data sheet

The following table provides information about the project.

Coordinator		 WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 2˙000˙000.00

Map

 Project objective

An important goal of stem cell therapy is to create “customized” cells that are genetically identical to the patient, which upon transplantation can restore damaged tissues. Such cells can be obtained by in vitro direct reprogramming of somatic cells into embryonic stem (ES)-like cells, termed induced pluripotent stem cells (iPSC). This approach also opens possibilities for modelling human diseases in vitro. However, major hurdles remain that restrain fulfilling conventional human iPSC/ESC potential, as they reside in an advanced primed pluripotent state. Such hurdles include limited differentiation capacity and functional variability. Further, in vitro iPSC based research platforms are simplistic and iPSC based “humanized” chimeric mouse models may be of great benefit. The recent isolation of distinct and new “mouse-like” naive pluripotent states in humans that correspond to earlier embryonic developmental state(s), constitutes a paradigm shift and may alleviate limitations of conventional primed iPSCs/ESCs. Thus, our proposal aims at dissecting the human naïve pluripotent state(s) and to unveil pathways that facilitate their unique identity and flexible programming. Specific goals: 1) Transcriptional and Epigenetic Design Principles of Human Naïve Pluripotency 2) Signalling Principles Governing Human Naïve Pluripotency Maintenance and Differentiation 3) Defining Functional Competence and Safety of Human Naïve Pluripotent Stem Cells in vitro 4) Novel human naïve iPSC based cross-species chimeric mice for studying human differentiation and disease modelling in vivo. These aims will be conducted by utilizing engineered human iPSC/ESC models, CRISPR/Cas9 genome-wide screening, advanced microscopy and ex-vivo whole embryo culture methods. Our goals will synergistically lead to the design of strategies that will accelerate the safe medical application of human naive pluripotent stem cells and their use in disease specific modelling and applied stem cell research.

 Publications

year authors and title journal last update
List of publications.
2019 Asaf Zviran, Nofar Mor, Yoach Rais, Hila Gingold, Shani Peles, Elad Chomsky, Sergey Viukov, Jason D. Buenrostro, Roberta Scognamiglio, Leehee Weinberger, Yair S. Manor, Vladislav Krupalnik, Mirie Zerbib, Hadas Hezroni, Diego Adhemar Jaitin, David Larastiaso, Shlomit Gilad, Sima Benjamin, Ohad Gafni, Awni Mousa, Muneef Ayyash, Daoud Sheban, Jonathan Bayerl, Alejandro Aguilera-Castrejon, Rada Massar
Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules
published pages: 328-341.e9, ISSN: 1934-5909, DOI: 10.1016/j.stem.2018.11.014 		Cell Stem Cell 24/2 2019-07-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CELLNAIVETY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CELLNAIVETY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More